Strides Shasun receives approval for Nystatin and Triamcinolone Acetonide Ointment

First topical approval from flagship plant in Bangalore

Strides Shasun announced that it's wholly owned subsidiary Strides Pharma Global has received approval for Nystatin and Triamcinolone Acetonide Ointment USP, 0.1% from the United States Food & Drug Administration (USFDA). This is the first topical approval received from the new semi solids block at the flagship plant in Bangalore. The topical product line is an important new addition to Strides' portfolio of oral solid dosage products and the Bangalore manufacturing plant supports several current and future topical submissions for the US Market. The product received approval within ten months under the GDUFA regime.

Powered by Capital Market - Live News